Jim Cramer declared Allergan (AGN) , not Bristol-Myers Squibb (BMY) , the new pharma growth stock. Cramer listed companies that are also lagging behind Allergan, like Merck (MRK) , Pfizer (PFE) , Glaxo Smithkline (GLAXF) and AstraZeneca (AZN) .
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.